BACKGROUND: Care of patients with locally recurrent rectal cancer (LRRC) requires careful patient selection. While curative resection offers survival benefits, significant trade-offs exist for the patient. Knowledge of patient-reported outcomes will help inform treatment decisions. METHODS: Quality of life (QOL) and pain were prospectively assessed in 105 patients treated for LRRC at a single institution, using the validated Functional Assessment of Cancer Therapy-Colorectal (FACT-C) and Brief Pain Inventory (BPI) questionnaires. In 54 patients enrolled and followed from diagnosis of LRRC, relationship between pretreatment pain, QOL, and overall survival (OS) were examined. RESULTS: Patients underwent curative surgical resection (C, 59%), noncurative surgery (NC, 12%) or nonsurgical treatment (NS, 28%). Median OS was 7.1, 1.4, and 1.9 years, respectively (C versus NC: p < 0.001; C versus NS: p = 0.006; NC versus NS: p = 0.261). Physical well-being QOL differed over time (p = 0.042), with greatest difference between C and NC surgery patients (p = 0.049). The remaining QOL domain scores and pain scores demonstrated no significant time or treatment effect. For the 54 patients assessed from diagnosis, median OS was independently predicted by treatment group (C, NC, NS: 4.3, 1.7, versus 2.4 years; p < 0.001) and pretreatment pain intensity (score ≤ 4 versus > 4: 3.8 versus 2.0 years; p = 0.001). CONCLUSION: Curative surgery offered prolonged survival, but significant pain exists among long-term survivors and should be a focus of survivorship care. Noncurative surgery did not offer apparent advantages over nonsurgical palliation. Patient's pretreatment pain has prognostic value, and should be assessed, treated, and considered in treatment decisions.
BACKGROUND: Care of patients with locally recurrent rectal cancer (LRRC) requires careful patient selection. While curative resection offers survival benefits, significant trade-offs exist for the patient. Knowledge of patient-reported outcomes will help inform treatment decisions. METHODS: Quality of life (QOL) and pain were prospectively assessed in 105 patients treated for LRRC at a single institution, using the validated Functional Assessment of Cancer Therapy-Colorectal (FACT-C) and Brief Pain Inventory (BPI) questionnaires. In 54 patients enrolled and followed from diagnosis of LRRC, relationship between pretreatment pain, QOL, and overall survival (OS) were examined. RESULTS:Patients underwent curative surgical resection (C, 59%), noncurative surgery (NC, 12%) or nonsurgical treatment (NS, 28%). Median OS was 7.1, 1.4, and 1.9 years, respectively (C versus NC: p < 0.001; C versus NS: p = 0.006; NC versus NS: p = 0.261). Physical well-being QOL differed over time (p = 0.042), with greatest difference between C and NC surgery patients (p = 0.049). The remaining QOL domain scores and pain scores demonstrated no significant time or treatment effect. For the 54 patients assessed from diagnosis, median OS was independently predicted by treatment group (C, NC, NS: 4.3, 1.7, versus 2.4 years; p < 0.001) and pretreatment pain intensity (score ≤ 4 versus > 4: 3.8 versus 2.0 years; p = 0.001). CONCLUSION: Curative surgery offered prolonged survival, but significant pain exists among long-term survivors and should be a focus of survivorship care. Noncurative surgery did not offer apparent advantages over nonsurgical palliation. Patient's pretreatment pain has prognostic value, and should be assessed, treated, and considered in treatment decisions.
Authors: Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab Journal: N Engl J Med Date: 2004-10-21 Impact factor: 91.245
Authors: Nestor F Esnaola; Scott B Cantor; Margo L Johnson; Attiqa N Mirza; Alexander R Miller; Steven A Curley; Christopher H Crane; Charles S Cleeland; Nora A Janjan; John M Skibber Journal: J Clin Oncol Date: 2002-11-01 Impact factor: 44.544
Authors: Dieter Hahnloser; Heidi Nelson; Leonard L Gunderson; Imran Hassan; Michael G Haddock; Michael J O'Connell; Stephen Cha; Daniel J Sargent; Alan Horgan Journal: Ann Surg Date: 2003-04 Impact factor: 12.969
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: C S Cleeland; R Gonin; A K Hatfield; J H Edmonson; R H Blum; J A Stewart; K J Pandya Journal: N Engl J Med Date: 1994-03-03 Impact factor: 91.245
Authors: C de Chaisemartin; C Penna; D Goere; S Benoist; A Beauchet; C Julie; B Nordlinger Journal: Colorectal Dis Date: 2008-04-28 Impact factor: 3.788
Authors: Naruhiko Ikoma; Y Nancy You; Brian K Bednarski; Miguel A Rodriguez-Bigas; Cathy Eng; Prajnan Das; Scott Kopetz; Craig Messick; John M Skibber; George J Chang Journal: J Clin Oncol Date: 2017-06-28 Impact factor: 44.544
Authors: Y N You; J M Skibber; C-Y Hu; C H Crane; P Das; E S Kopetz; C Eng; B W Feig; M A Rodriguez-Bigas; G J Chang Journal: Br J Surg Date: 2016-03-02 Impact factor: 6.939
Authors: Garrett Jensen; Randa Tao; Cathy Eng; John M Skibber; Miguel Rodriguez-Bigas; George J Chang; Y Nancy You; Brian K Bednarski; Bruce D Minsky; Eugene Koay; Cullen Taniguchi; Sunil Krishnan; Prajnan Das Journal: Adv Radiat Oncol Date: 2018-07-17